Cell Cycle and Cell Death Regulation
Mark Meuth (University of Sheffield, UK) explained the cell cycle regulation and its disruption in cancerous conditions. His major topic of interest was DNA damage response-mediated killing of tumor cells. He established a novel role of CHK1 in suppression of apoptosis and as a potential therapeutic target in cancer. Sagar Sengupta (NII, New Delhi) reported specific CHK1-dependent phosphorylation sites on BLM helicase following DNA damage.
WS El-Deiry (Penn state Hershey Cancer Institute, USA) illustrated targeted cell death in cancer therapy and discussed theories over p53 regulation in cancer. He also described novel strategies to develop anticancer agents, based on the p53-related biochemical pathways. Gerry Melino (University Tor Vergata, Italy; Medical Research Council, UK), described the effect of the p53 family proteins, like p73 and p63; p73 null mice showed hippocampal dysegensis in the process of neuronal development. Here, p73 acts as a transcriptional activator of miR-34a. K Sakaguchi (Hokkaido University, Japan) explained abnormal nucleolar formation by overexpression of p53-inducible protein phosphatase PPM1D, which modulated the nucleolar formation via nucleophosmin in breast cancer cells.
Systems Biology Approach to Fight Cancer
ET Liu (Genomic Institute of Singapore, Singapore), in his lecture entitled 'Genome-to-Systems Biology in Cancer Medicine', emphasized the need for systems biology approaches in cancer research and discussed the current ability to sequence cancer genomes in a cost-effective manner. This will allow identification of unique and private mutations for individual patient that will be helpful to develop personalized therapy against cancer. TJ Hudson (Ontario Institute for Cancer Research, Canada) illustrated the genomic variations in cancer in different human populations and elaborated aims of International Cancer Genome Consortium (ICGC). The aim is to generate comprehensive catalogs of genomic abnormalities in Death and Differentiation (2011 ) 18, 1675 -1677 50 different cancer types and make the data available as rapidly as possible, with minimal limitations to scientists to accelerate research for management of cancer. PP Majumder (National Institute of Biomedical Genomic, Kalyani, India) also described ICGC and role of Indian initiatives to make it better and broader.
Genetics, Epigenetics and Transcription
K Somasundaram (IISc, Bangalore) explained epigenetics of glioma and astrocytoma development in relation to DNA methylation and microRNA regulation. On the epigenetic regulations, Subrata Sinha (NBRC, Haryana) described that heterochromatization and suppressing oncogene expression with consequent phenotypic changes resulting from the reactivation of the p53 and RB-mediated tumor suppressor pathways in cancer. M Bashyam (CDFD, Hyderabad) told that unique DNA lesions MLH1/MSH2 inactivation may account for a majority of non-polyposis colorectal cancer cases in India. SC Raghavan (IISc, Bangalore) and Manoj Mahimkar (ACTREC, Mumbai) described the chromosomal aberration and translocation in different cancerous condition and their potential role for the malignant propagation. Rajiv Kumar (German Cancer Research Center, Germany) demonstrated different genetic mutations of CDKN2A, PTEN, NRAS, EGFR, MITF, NOTCH2, CCND1, MDM2, CCNE1 and CDK4 genes in malignant melanoma. Similarly, CK Panda (CNCI, Kolkata) identified defect in several genes of EGFR, retinoblastoma and p53-associated pathways in oral cancer. Apart from the nucleus-associated genes, Bidyut Roy (ISI, Kolkata) illustrated the role of mitochondria and mitochondria-associated genes and significant association of SNP rs9905016 in the POLG2 gene with pre-cancerous stages of oral cancer. TK Kundu (JNCASR, Bangalore) illustrated histone hyperacetylation in H3K14, K9 and H2AK5 residues in oral cancer patients and claimed that histone acetylation inhibition could be a potential epigenetic target. Sanghamitra Banerjee (ISI, Kolkata) and Subrata Banerjee (SINP, Kolkata) shared their knowledge on the topic of genetics and genomics.
Transcription and transcriptomics was indeed a very hot field of interest. CK Sinha (University of Michigan, USA) elaborated his view on high-throughput transcriptome sequencing of cancers and ideas/possibilities to produce personalized medicine. Different transcription factors and their mode of action in cancers were explored by SK Manna (CDFD, Hyderabad) and Shantanu Chowdhury (CSIR-IGIB, New Delhi). They proved that Rel-A and NME2 transcriptionally controls cancer progression and metastases. S Chattopadhyay (NCCS, Pune) focused the role of SMAR1 as a transcriptional repressor in cancer, which modulated the transactivation potential of transcriptional co-activators NF-kB and p53. SMAR1 facilitated DSB repair by assisting in anchorage of DNA repair factors at the site of repair and causing cell cycle arrest, allowing proper repair.
Basic and Clinical Therapeutics
Chitra Mandal (CSIR-IICB, Kolkata) illustrated the role of sialic acid in search of drug target. She demonstrated a significant correlation with newly induced 9-O-acetylated sialoglycoproteins/sialoglycolipids and sialate O-acetyl transferase enzyme with the high-risk acute lymphoblastic leukemia. Therefore, sialylation regulatory enzymes may be considered as potential target. S Raha (SINP, Kolkata) said that resveratrol targets key survival elements in cancer and causes apoptosis. TR Teni (ACTREC, Mumbai) illustrated radiation therapy in oral squamous cells and role of different apoptosis regulatory proteins (Mcl-1, Bcl-Xl, survivin, p53 and p16). D Panda (IIT, Mumbai) showed that inhibition of microtubule dynamics blocks mitosis and retards cell division and migration and may consider as therapeutic target in cancer. Identification of disease marker through immunoproteomics was discussed by Surekha Zingde (ACTREC, Mumbai).
Cancer Immunology and Signaling
SV Chiplunkar (ACTREC, Mumbai) emphasized the role of notch and Toll-like receptors in regulating the effector functions of dg-T lymphocytes. Neeta Singh (AIIMS, New Delhi) established a synthetic peptide from HPV-16 to produce better immunoadjuvant activity in vaccination against cervical cancer. Anil Suri (NII, New Delhi) presented a firm relationship between SPAG9 protein expression and humoral immune response in majority of early-stage colorectal cancer patients, indicating that circulating anti-SPAG9 antibodies could be a novel serum biomarker for early diagnosis. B Mukherji (University of Connecticut, USA) talked about T-cell mediated cancer immune therapy. Arun Dharmarajan (The University of Western Australia, Australia) convincingly demonstrated the anti-angiogenic role of secreted frizzledrelated protein 4 and its possible therapeutic applications in the treatment of angiogenesis-dependent pathologies like cancer. MK Ghosh (CSIR-IICB, Kolkata) illustrated the cross talk of different signaling pathways like Wnt/b-catenin and EGFR in glioma, breast and prostate cancer. Ellora Sen (NBRC, Haryana) described the role of TNF-a induced TLR4 in signaling events that sustained tumor promoting proinflammatory microenvironment of glioma. The newly-identified cancer stem cell was described by Tanya Das (Bose Institute, Kolkata) and she mainly demonstrated the signaling process by which a resistant cancer stem cell become prone to apoptosis. PS Dasgupta (CNCI, Kolkata) described that neurotransmitter dopamine act as an endogenous regulator of angiogenesis in cancer. In the absence of dopaminergic receptor, tumor growth was enhanced by angiogenesis suggesting dopamine as an anti-angiogenic factor. S Ashraf Imam (HMRI, USA) explained in vitro three-dimensional human breast cancer model, which consists of cancer, stromal cells and mimics tissue-like microenvironment. SG Rhee (EWHA Woman's University, Korea) discussed role of alcohol-induced oxidative injury of liver. SN Dalal (ACTREC, Mumbai) discussed about neoplastic progression and its relation with desmosome formation.
Concluding Remarks
The scope of cancer research is vast and expanding. This wonderful gathering provided a succinct update on current basic research in cancer biology and new therapeutic approaches in cancer treatment. Even though a number of mechanisms have been resolved, lots of questions still remain and more come up as novel thoughts emerged. As a result, the IACR platform truly emerged as the melting pot of novel ideas from East and West. The meeting ended with great optimism that the intense interactions among the participants would lead to more future collaborations.
